Company intelligence / Profile preview
Haichang Biotech
Hangzhou, Zhejiang, China
- Ownership
- Private
- Employees
- ~162
- Development stage
- Other
01
Overview
Lead candidates include clinical-stage lipid nanoparticle therapies targeting oncology and immunotherapy indications; completed Phase I US trials with multicenter activity (including HCC, lung, and pancreatic cancer), advanced to Phase II in China and Hong Kong, with IND/Phase I for TLR9 agonist in immunotherapy. First-generation PEGylated liposomal doxorubicin approved and commercialized. Preclinical/early clinical expansion ongoing in RNA drugs and metabolic disorders.
- Therapeutic areas
- EndocrinologyInfectious DiseasesMetabolic DisordersRare DiseasesOncology
- Modalities
- Lipid nanoparticle delivery therapyAntisense oligonucleotidemRNA-based drugsSmall moleculeBiologicProphylactic vaccineOligonucleotide
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Rexahn Pharmaceuticals
Beyond the preview
Go deeper on Haichang Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haichang Biotech.